Chinese researchers employed a new online consultation tool to improve disease management for patients with rheumatic diseases who travel long distances for a consultation with their rheumatologist and noted significant savings for the patients.
A new online consultation tool may strengthen the interaction between physicians and their patients with rheumatic diseases, according to new research presented at the 2017 American College of Rheumatology Annual Meeting.
Researchers in China developed the new tool to provide more efficient management of chronic illnesses. The Smart System of Disease Management (SSDM) is a series of applications based on clinical data and a mobile app that allows for online consultation.
In China, patients can seek care in any hospital or with any doctor they want, but those with rheumatic disease tend to seek care in large cities, because that is where the rheumatologists are located. This results in patients traveling long distances and even staying at hotels to see a clinician after a long wait.
“It is not uncommon for most Chinese rheumatologists to have to see up to 60 to 100 patients daily.” Fei Xiao, MD, CEO of Cinkate Corporation and a lead author of the study, explained in a statement. “Because of the large volume of patients who go to major hospitals for regular clinical care, physicians may only spend three minutes on average with each patient. This limits the time to do objective disease activity evaluations.”
Patients trained to use SSDM are able to perform self-management for their condition, including disease activity scoring of 28 joints, health assessment evaluations, and medication and lab test data entry. The study aimed to determine the benefits of using SSDM for online consultation.
Rheumatologists educated and trained patients on using SSDM, which includes a doctor/patient interface, a self-assessment, medication management, adverse events management, and laboratory records. After patients submit their data to their doctor, the provider may follow-up in person with patients or consult through text or voice with SSDM. Overall, 66.35% of patients said they found their experience with the online consultation “very satisfying.”
More than one-third (35.3%) of the patients who received online consultations lived in a different city than their rheumatologist. As a result, using SSDM saved a significant amount of money. The total fees collected for SSDM consultations was 477,960 yuan RMB; the total cost for patients seeking care at a hospital, including the cost of registration fees, medical expenses, and the average cost of transportation, accommodations, meals, and lost wages was 3,157,200 yuan RMB. In total, the online consultation created a savings of 84.86% for patients.
According to Xiao, patients and providers will benefit from SSDM, with patients more empowered to input data and follow their disease progression, and physicians able to mine and analyze data for research and publication.
“Access to this online program also helps physicians to mine and analyze data for scientific research and publication,” he said. “Based on the trajectory and real-time data, such as disease activity score, lab results, medication and patient’s symptoms, physicians are able to take proactive interventions, and turn passive practice into outcome-driven care. This model can be replicated into the other disciplines and fields of chronic disease.”
AMCP Posters Tackle Interchangeability and Medicaid, Factors Driving Biosimilar Access
April 24th 2024Two posters from the Academy of Managed Care Pharmacy (AMCP) annual meeting explore how an interchangeable insulin glargine biosimilar plays into Medicaid budgets and the top factors driving access to biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.